Literature DB >> 29298274

Plasma apolipoprotein-B is an important risk factor for cardiovascular disease, and its assessment should be routine clinical practice.

Stella Trompet1,2, Chris J Packard3, J Wouter Jukema2,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29298274     DOI： 10.1097/MOL.0000000000000476

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN： 0957-9672            Impact factor:   4.776


× No keyword cloud information.
  4 in total

1.  Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease.

Authors:  Claire Welsh; Carlos A Celis-Morales; Rosemary Brown; Daniel F Mackay; James Lewsey; Patrick B Mark; Stuart R Gray; Lyn D Ferguson; Jana J Anderson; Donald M Lyall; John G Cleland; Pardeep S Jhund; Jason M R Gill; Jill P Pell; Naveed Sattar; Paul Welsh
Journal:  Circulation       Date:  2019-06-20       Impact factor: 29.690

Review 2.  Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease.

Authors:  Chris J Packard
Journal:  Curr Atheroscler Rep       Date:  2022-02-17       Impact factor: 5.113

3.  Apolipoprotein B and renal function: across-sectional study from the China health and nutrition survey.

Authors:  Wenbo Zhao; Junqing Li; Xiaohao Zhang; Xiaomei Zhou; Junyi Xu; Xun Liu; Zifeng Liu
Journal:  Lipids Health Dis       Date:  2020-05-27       Impact factor: 3.876

4.  Increased serum concentration of apolipoprotein B is associated with an increased risk of reaching renal replacement therapy in patients with diabetic kidney disease.

Authors:  Wen-Bo Zhao; Lin Zhu; Tohty Rahman
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.